Clinical Trial Update: Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating omalizumab in combination with allergy shots for seasonal allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hay Fever, Hypersensitivity | Phase 2 | Status: COMPLETED